Impact of a bi-annual community-directed treatment with ivermectin programme on the incidence of epilepsy in an onchocerciasis-endemic area of Mahenge, Tanzania: A population-based prospective study

Author:

Bhwana Dan,Amaral Luís-Jorge,Mhina Athanas,Hayuma Paul Martine,Francis Filbert,Siewe Fodjo Joseph N.,Mmbando Bruno P.,Colebunders RobertORCID

Abstract

BackgroundCommunity-directed treatment with ivermectin (CDTi) is used to eliminate onchocerciasis. However, despite 25 years of annual CDTi in Mahenge, Tanzania, the prevalence of onchocerciasis and onchocerciasis-associated epilepsy remained high in certain rural villages. Therefore, in 2019, bi-annual CDTi was introduced in the area. This study assessed the impact of the programme on the incidence of epilepsy in four villages.MethodologyDoor-to-door epilepsy surveys were conducted prior to (2017/18) and after (2021) implementing a bi-annual CDTi program. All household members were screened for epilepsy symptoms using a validated questionnaire, and suspected cases were examined by a medical doctor to confirm/reject the diagnosis of epilepsy. The prevalence and annual incidence of epilepsy, including nodding syndrome, were calculated with 95% Wilson confidence intervals with continuity correction. The latter was also done for CDTi coverage in 2016 and 2021.ResultsPrecisely 5,444 and 6,598 persons were screened for epilepsy before and after implementing the intervention. The CDTi coverage of the overall population was 82.3% (95%CI: 81.3–83.2%) in 2021 and sustained in both distribution rounds (81.5% and 76.8%). The coverage was particularly high in children and teenagers aged 6 to 18 years (93.2%, 95%CI: 92.1–94.2%). The epilepsy prevalence remained similar: 3.3% (95%CI: 2.9–3.9%) in 2017/18 versus 3.1% (95%CI: 2.7–3.5%) in 2021. However, the incidence of epilepsy declined from 177.6 (95%CI: 121.2–258.5) in 2015–2017 and 2016–2018 to 45.5 (95%CI: 22.2–89.7) in 2019–2021 per 100,000 persons-years. The incidence of probable nodding syndrome varied from 18.4 (95%CI: 4.7–58.5) to 5.1 (95%CI: 0.3–32.8). None of the nine incidence cases of epilepsy for which information on ivermectin intake was available took ivermectin in the year they developed their first seizures.ConclusionA bi-annual CDTi programme should be implemented in areas with high prevalence of onchocerciasis and epilepsy. High CDTi coverage among children is particularly important to prevent onchocerciasis-associated epilepsy.

Funder

VLIR-UOS

FWO

“la Caixa” Foundation

Publisher

Public Library of Science (PLoS)

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Reference31 articles.

1. Onchocerca volvulus and epilepsy: A comprehensive review using the Bradford Hill criteria for causation;R Colebunders;PLoS Negl Trop Dis,2021

2. World Health Organization. Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures Geneva: World Health Organization; 2016 [updated 2016. https://apps.who.int/iris/handle/10665/204180.

3. Onchocerciasis—level 3 cause;Global Health Metrics;Lancet,2020

4. Periodic reproduction of Onchocerca volvulus;H Schulz-Key;Parasitol Today,1986

5. El síndrome epiléptico y sus relaciones con la oncocercosis;G. Casis-Sacre;Bol Salub Hig,1938

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3